Rock ‘n’ Roll Marathon Series
The first physician to launch a successful career in the healthcare investment sector, Mitchell invests in healthcare companies as the founder of Consonance Capital in New York. Mitchell Blutt also formerly served on the board of directors for the Michael J. Fox Foundation, which welcomes members of the public to contribute toward finding a cure for Parkinson’s by joining Team Fox for athletic events such as the 2017 Rock ‘n’ Roll Marathon Series.
The Rock ‘n’ Roll Marathon Series began with the simple idea of a marathon with bands positioned along the course to cheer on participants. Celebrating its 20th year, the event has grown into a nationwide series of marathons consisting of a weekend of entertainment and runs to support participating charities. The world-class Health and Fitness Expo takes place alongside the marathon. The event concludes with a concert featuring big name musical performers.
Team Fox will participate in two upcoming marathons in the 2017 Rock n’ Roll Series: one in Brooklyn, New York, on October 14 and one in San Antonio, Texas, on December 2 through December 3. Runners who become a member of Team Fox will receive guaranteed entry into the race, running singlet for race day, and a personal fundraising page. Runners must commit to a specific fundraising goal based on race participation and those who meet their goal will receive a commemorative medal.
Addiction Speaker Series
Mitchell Blutt, MD, is CEO and founder of Consonance Capital , a healthcare investment firm based in New York City. Dr. Mitchell Blutt also serves as a clinical assistant professor at Weill Cornell Medical College and is a former member of the advisory board for CASA, The National Center on Addiction and Substance Abuse.
CASA, founded in 1992, strives to “connect science with policy and practice” in the field of addiction and substance abuse, with the ultimate goal of improving the lives of those afflicted both directly and indirectly by this destructive illness.
To date, CASA researchers have published more than 200 articles on substance abuse and addiction. In addition, the organization is dedicated to keeping the public informed on the importance of preventing substance use by children, and the misunderstood nature of addiction, which is often seen as a choice rather than an illness. CASA also highlights nationwide shortcomings such as the mere two cents of every dollar of federal spending received each year for addiction prevention and treatment.
The organization’s Addiction Speaker Series brings in experts whose talks on topics as diverse as “Digital Interventions to Reduce Problem Substance Use” and “Adolescent Substance Misuse Prevention” are available both live at CASA’s New York office, and as webinars. The series is free but the live events require registration.
Francis E. Johnston
A respected voice in the health care investment sector, Mitchell Blutt, MD, serves as chief executive officer of Consonance Capital in New York City. An alumnus of the University of Pennsylvania, Mitchell Blutt, MD, serves on the Board of Overseers for the college’s School of Arts and Sciences.
The University of Pennsylvania’s School of Arts and Sciences recently announced that Harold L. Dibble will serve as the school’s Francis E. Johnston Endowed Term Professor. An anthropology professor at the school, Dibble is also the main curator for the Penn Museum’s European archaeology area and has previously served on the museum’s Laboratory Committee, along with other key positions during his career at Penn.
A leading anthropological researcher, Dibble specializes in Paleolithic human origin studies focused on North Africa and Western Europe. In his research work, he leads two high-profile archaeological digs in the Pech de l’Azé IV and La Ferrassie areas of France.
As CEO of Consonance Capital, Dr. Mitchell Blutt guides private equity funds and health care investments. Community focused, Dr. Mitchell Blutt supports a number of nonprofits and is a past board member of the Michael J. Fox Foundation, which is working to find a cure for Parkinson’s disease.
Impacting 10 million people across the globe, Parkinson’s disease is a neurological condition that results in deterioration of physical function, with uncontrollable tremors leading to nerve cells misfiring and dying within the brain. Still incurable, Parkinson’s disease is not fully understood by medical researchers.
A recently published study by the Okinawa Institute of Science and Technology Graduate University revealed the protein that blocks the proper transmission of neural signals that underpin higher brain functioning. Neurotransmission enables neurons to communicate signals effectively and transfer them in ways that allow seamless sensory motor functioning.
The chemical messengers contained in vesicle endocytosis within the nerve terminal are essential in transmitting neurological signals. When the process of endocytosis is inhibited during times of heavy use, processes breakdown and sensory perception of motor control is affected. Understanding this inhibitory process promises to offer a vital step toward tailoring treatments to actual neurological conditions in ways that have a positive for among patients.